Valuation: Structure Therapeutics Inc.

Market Cap 3.27B 2.86B 2.64B 2.43B 4.59B 315B 4.67B 31.54B 12.39B 154B 12.29B 12.02B 531B P/E 2026 *
-32.2x
P/E 2027 * -22.1x
Enterprise Value 2.2B 1.92B 1.78B 1.63B 3.09B 212B 3.14B 21.2B 8.33B 103B 8.26B 8.08B 357B EV / Sales 2026 *
57.2x
EV / Sales 2027 * 60,761x
Free-Float
76.06%
Yield 2026 *
-
Yield 2027 * -
1 day-7.23%
1 week-16.52%
Current month-14.24%
1 month+7.27%
3 months-13.96%
6 months-48.07%
Current year-33.82%
1 week 45.97
Extreme 45.97
53
1 month 43.98
Extreme 43.985
57.07
Current year 35.78
Extreme 35.78
94.77
1 year 15.8
Extreme 15.8
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Tech/Sci/R&D Officer 52 18/09/2024
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap.
14/07/26 Fiscal year

Chief Technology Officer

86,658 0.0620%
25/06/26 Fiscal year

Chief Technology Officer

86,658 0.0620%
17/06/26 Free

Chairman

39,453 0.0282%
Change 5-day change 1-year change 3-year change Capi.($)
-7.23%-16.52%+134.85%+36.59% 3.27B
-3.42%+4.90%+61.15%+87.70% 55.98B
-1.92%-3.64%+49.96%+68.19% 53.69B
-2.14%-9.13%+2.74%+421.65% 23.29B
-0.47%-1.53%-18.61%-15.41% 23.15B
-5.95%-2.58%+30.67%-9.47% 20.58B
-1.81%-0.62%+30.73%-30.86% 17.76B
-4.55%-1.95%+192.65%+349.58% 16.09B
-6.91%-5.83%+26.53%+644.30% 15.93B
+0.23%-2.49%+24.26%+187.16% 14B
Average -3.70%-2.04%+53.49%+173.94% 24.38B
Weighted average by Cap. -3.09%-1.09%+46.03%+147.37%

Financials

2026 *2027 *
Net sales 38.46M 33.62M 31.09M 28.53M 54M 3.71B 54.93M 371M 146M 1.81B 144M 141M 6.25B 41.67K 36.42K 33.68K 30.91K 58.5K 4.02M 59.52K 402K 158K 1.96M 156K 153K 6.77M
Net income -288M -251M -232M -213M -404M -27.71B -411M -2.77B -1.09B -13.53B -1.08B -1.06B -46.72B -423M -370M -342M -314M -594M -40.77B -604M -4.08B -1.6B -19.91B -1.59B -1.55B -68.74B
Net Debt -1.07B -938M -867M -796M -1.51B -103B -1.53B -10.34B -4.06B -50.49B -4.03B -3.94B -174B -740M -647M -598M -549M -1.04B -71.27B -1.06B -7.13B -2.8B -34.8B -2.78B -2.72B -120B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
233
Date Price Change Volume
16/07/26 $46.03 -7.23% 654,227
15/07/26 $49.62 -1.92% 684,482
14/07/26 $50.59 -2.03% 565,872
13/07/26 $51.64 -3.22% 490,987
10/07/26 $53.36 -3.23% 736,852
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
46.03USD
Average target price
104.59USD
Spread / Average Target
+127.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock